EP4061485A4 - Methods of treating glioblastoma - Google Patents

Methods of treating glioblastoma Download PDF

Info

Publication number
EP4061485A4
EP4061485A4 EP20890680.0A EP20890680A EP4061485A4 EP 4061485 A4 EP4061485 A4 EP 4061485A4 EP 20890680 A EP20890680 A EP 20890680A EP 4061485 A4 EP4061485 A4 EP 4061485A4
Authority
EP
European Patent Office
Prior art keywords
methods
treating glioblastoma
glioblastoma
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20890680.0A
Other languages
German (de)
French (fr)
Other versions
EP4061485A1 (en
Inventor
Laurence James Neil COOPER
Jill Yannetti BUCK
Arnold Bruce GELB
Nathan Aubri DEMARS
Nira HADAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alaunos Therapeutics Inc
Original Assignee
Alaunos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alaunos Therapeutics Inc filed Critical Alaunos Therapeutics Inc
Publication of EP4061485A1 publication Critical patent/EP4061485A1/en
Publication of EP4061485A4 publication Critical patent/EP4061485A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
EP20890680.0A 2019-11-22 2020-11-20 Methods of treating glioblastoma Pending EP4061485A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962939471P 2019-11-22 2019-11-22
US202063025749P 2020-05-15 2020-05-15
US202063113018P 2020-11-12 2020-11-12
PCT/US2020/061546 WO2021102287A1 (en) 2019-11-22 2020-11-20 Methods of treating glioblastoma

Publications (2)

Publication Number Publication Date
EP4061485A1 EP4061485A1 (en) 2022-09-28
EP4061485A4 true EP4061485A4 (en) 2023-12-20

Family

ID=75980880

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20890680.0A Pending EP4061485A4 (en) 2019-11-22 2020-11-20 Methods of treating glioblastoma

Country Status (3)

Country Link
US (1) US20230399370A1 (en)
EP (1) EP4061485A4 (en)
WO (1) WO2021102287A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2207874B1 (en) * 2007-10-08 2014-12-03 Intrexon Corporation Engineered dendritic cells and uses for the treatment of cancer
CA2739902A1 (en) * 2008-10-08 2010-04-15 Intrexon Corporation Engineered cells expressing multiple immunomodulators and uses thereof
US20170291934A1 (en) * 2014-09-22 2017-10-12 Charles C. Reed Improved therapeutic control of heterodimeric and single chain forms of interleukin-12

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARRETT JOHN A ET AL: "Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System (RTS ) gene switch as gene therapy for the treatment of glioma", CANCER GENE THERAPY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 25, no. 5, 14 May 2018 (2018-05-14), pages 106 - 116, XP036535330, ISSN: 0929-1903, [retrieved on 20180514], DOI: 10.1038/S41417-018-0019-0 *
CHIOCCA E. ANTONIO ET AL: "Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: Tolerability and survival in recurrent glioblastoma.", JOURNAL OF CLINICAL ONCOLOGY, vol. 35, no. 15_suppl, 20 May 2017 (2017-05-20), US, pages 2044 - 2044, XP055905565, ISSN: 0732-183X, Retrieved from the Internet <URL:https://ziopharm.com/atotsohe/2018/06/asco2017final.pdf> DOI: 10.1200/JCO.2017.35.15_suppl.2044 *
See also references of WO2021102287A1 *
VUJANOVIC L ET AL: "IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro", CANCER GENE THERAPY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 13, no. 8, 28 April 2006 (2006-04-28), pages 798 - 805, XP037757466, ISSN: 0929-1903, [retrieved on 20060428], DOI: 10.1038/SJ.CGT.7700964 *

Also Published As

Publication number Publication date
WO2021102287A1 (en) 2021-05-27
EP4061485A1 (en) 2022-09-28
US20230399370A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
EP3710102A4 (en) Methods of treating glioblastoma
EP3813808A4 (en) Methods of treating substance abuse
EP3645039A4 (en) Use of anti-fam19a5 antibodies for treating fibrosis
EP3773633A4 (en) Methods of treating glioblastomas
EP3565540A4 (en) Methods for treating cardiovascular diseases
EP3787625A4 (en) Methods of treating cancer
EP3952851A4 (en) Compounds and methods for treating inflammatory disorders
EP3908650A4 (en) Methods of treating cancer
EP3833752A4 (en) Method for the treatment of mucopolysaccharidosis type ii
EP4017490A4 (en) Compounds and methods for treating oxalate-related diseases
EP3914589A4 (en) Methods of treating disease with magl inhibitors
EP3952858A4 (en) Method of treating tumours
EP3886844A4 (en) Methods of treating disease with magl inhibitors
EP3784231A4 (en) Methods of treating hypertension
EP3655418A4 (en) Methods of treating glioblastoma
EP3852816A4 (en) Methods of treating cancer
EP4072561A4 (en) Methods of treating cancer
EP3897642A4 (en) Methods of treating inflammation
EP4058140A4 (en) Methods of treating ascites
EP3937922A4 (en) Methods of treating organic acidemias
EP3914235A4 (en) Methods of treating addiction
EP3890780A4 (en) Method of treatment
EP4061485A4 (en) Methods of treating glioblastoma
EP3801547A4 (en) Methods of treating cancer
EP3781215A4 (en) Methods of treating cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220607

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081168

Country of ref document: HK

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230530

A4 Supplementary search report drawn up and despatched

Effective date: 20231115

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/63 20060101ALI20231110BHEP

Ipc: A61K 35/761 20150101ALI20231110BHEP

Ipc: A61P 35/00 20060101AFI20231110BHEP